Asset profile
Beclomethasone dipropionate/formoterol fumarate
Small molecule
Evidence outlook · lead readout
FORCE2 (NCT05292586) · Asthma
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
FORCE2 (NCT05292586): The study was randomized, quadruple-blinded, actively controlled, and included 576 randomized participants. Its primary clinical lung-function endpoint, change from baseline in 12-hour FEV1 AUC at week 12, favored beclomethasone dipropionate/formoterol over beclomethasone dipropionate alone and was statistically significant (p<0.001).
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 38 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Beclomethasone Dipropionate / Formoterol Fumarate: this drug | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | ||
| Albuterol (Armstrong Albuterol HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol / Budesonide (Airsupra) | Approved | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | ||
| Albuterol HFA (Armstrong's) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol HFA (Proventil HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Armstrong) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Albuterol Sulfate (Provenetil-HFA) | Approved | Small molecule | Beta-2 adrenergic receptor | ||
| Aminophylline | Approved | Small molecule | Phosphodiesterase (multi-subtype) | ||
| Beclomethasone (QVAR) | Approved | Small molecule | Glucocorticoid receptor | ||
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | ||
| Benralizumab (Fasenra) | Approved | Monoclonal antibody | IL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophils | ||
| Budesonide (Pulmicort) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | ||
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | ||
| Ciclesonide (Alvesco) | Approved | Small molecule | Glucocorticoid receptor | ||
| Depemokimab | Approved | Monoclonal antibody | IL-5 |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.